findmyKOL
Clinical trialNCT05057247CompletedPhase 2Interventional

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

SponsorGlenn J. HannaEnrollment26Advanced Head and Neck CancerAdvanced Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the Head and Neck (SCCHN)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Oct 2021
Primary completion
1 Oct 2023
Completion
13 Jun 2024
Last update posted
31 Oct 2025
Registered enrollment
26
Registry id
NCT05057247
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.